Sort
64,565 grants matching “drug discovery”
COBRE in Lipidomics and Pathobiology
$1,094,825Besim Ogretmen · Medical University Of South Carolina · P30 · FY2016 · GM
COBRE in Lipidomics and Pathobiology
$1,094,825Besim Ogretmen · Medical University Of South Carolina · P30 · FY2014 · GM
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,094,655Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Center for Genomics and Society
$1,094,421Gail E Henderson · Univ Of North Carolina Chapel Hill · P50 · FY2009 · HG
Adenosine Receptor Agonists as an Immunotherapy for Biodefense
$1,094,420Peter B Ernst · University Of Virginia · U01 · FY2009 · AI
(Epi)genetic Risk Architectures in Opioid Dependent Brain
$1,094,363Peter Christopher Scacheri · Case Western Reserve University · R01 · FY2017 · DA
Development of small molecule therapeutics for mitigating opioid withdrawal syndrome
$1,094,320Sid Ahmed Labed · Evodenovo, Inc. · R44 · FY2025 · DA
NIDA Center of Excellence OF Computational Drug Abuse Research (CDAR)
$1,094,316Xiang-Qun Xie · University Of Pittsburgh At Pittsburgh · P30 · FY2014 · DA
Boston OAIC: A Translational Approach to Function Promoting Anabolic Therapies
$1,094,232Shalendar Bhasin · Boston Medical Center · P30 · FY2012 · AG
Scalable Synthesis and New Bond Disconnections
$1,094,208Phil S Baran · Scripps Research Institute, The · R35 · FY2022 · GM
Scalable Synthesis and New Bond Disconnections
$1,094,208Phil S Baran · Scripps Research Institute, The · R35 · FY2021 · GM
Small Molecule Therapeutics for Renal Disease
$1,094,052Prakash Narayan · Angion Biomedica Corporation · R44 · FY2010 · DK
Phase 3 trial of inosine for Parkinson's disease - DCC
$1,093,787David Oakes · University Of Rochester · U01 · FY2015 · NS
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy
$1,093,421Maria Zoe Kounnas · Neurogenetic Pharmaceuticals, Inc. · R01 · FY2016 · AG
Countermeasures Against Chemical Threats ^ Preclinical Development Facility
$1,093,306Carol E Green · Sri International · N01 · FY2015 · NS
Activity-based Sensor Peptides for Direct, High-throughput, and Kinetic Quantitation of Oncogenic Protein Kinases in Unfractionated Cell and Tissue Samples
$1,093,104Erik Michael Schaefer · Assayquant Technologies, Inc. · R44 · FY2024 · CA
Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)
$1,092,964Jeffrey H. Price · Vala Sciences, Inc. · R44 · FY2025 · MH
Novel Small-Molecule Therapies for CF
$1,092,849Alan S Verkman · University Of California, San Francisco · P30 · FY2014 · DK
RESBIO - the Technology Resource for Polymeric Biomaterials
$1,092,452Joachim B. Kohn · Rutgers, The State Univ Of N.J. · P41 · FY2010 · EB
Center for Cancer Experimental Therapeutics
$1,092,304Barbara Timmermann · University Of Kansas Lawrence · P30 · FY2012 · GM
Regulatory landscape of the human genome: comparative and evolutionary analysis.
$1,092,257Ivan Ovcharenko · National Library Of Medicine · ZIA · FY2017 · LM
Inhibition Of Renal Injury
$1,092,242Robert A Star · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Impact of gene-drive systems for population modification on malaria vector mosquitoes
$1,092,110Anthony A James · University Of California-Irvine · R01 · FY2023 · AI
Targeted Discovery of Marine-derived Anticancer Leads
$1,092,108Phil Crews · University Of California Santa Cruz · U19 · FY2008 · CA
High Throughput DSC for Drug Screening
$1,092,099Energetic Genomics Corporation · R44 · FY2005 · CA